Integer Holdings (ITGR) | Financial Analysis & Statements
Integer Holdings Corporation Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
472.1M
Gross Profit
124.8M
26.43%
Operating Income
54.5M
11.56%
Net Income
48.6M
10.30%
Balance Sheet Metrics
Total Assets
3.4B
Total Liabilities
1.7B
Shareholders Equity
1.7B
Debt to Equity
0.95
Cash Flow Metrics
Operating Cash Flow
51.8M
Free Cash Flow
28.9M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Integer Holdings Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.9B | 1.7B | 1.6B | 1.4B | 1.2B |
| Cost of Goods Sold | 1.4B | 1.3B | 1.2B | 1.0B | 884.1M |
| Gross Profit | 500.4M | 459.0M | 418.3M | 359.0M | 337.0M |
| Gross Margin % | 27.0% | 26.7% | 26.2% | 26.1% | 27.6% |
| Operating Expenses | |||||
| Research & Development | 49.5M | 53.4M | 63.8M | 60.9M | 52.0M |
| Selling, General & Administrative | 211.7M | 185.2M | 175.6M | 160.6M | 141.4M |
| Other Operating Expenses | - | - | 2.1M | 1.2M | 508.0K |
| Total Operating Expenses | 261.2M | 238.6M | 241.5M | 222.7M | 193.9M |
| Operating Income | 239.1M | 220.4M | 178.9M | 137.5M | 143.6M |
| Operating Margin % | 12.9% | 12.8% | 11.2% | 10.0% | 11.8% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 36.3M | 52.3M | 51.1M | 35.8M | 31.6M |
| Other Non-Operating Income | -71.4M | -16.4M | -17.0M | -23.8M | -10.9M |
| Pre-tax Income | 125.4M | 147.6M | 107.3M | 76.0M | 101.1M |
| Income Tax | 22.6M | 26.5M | 16.6M | 10.6M | 8.0M |
| Effective Tax Rate % | 18.0% | 18.0% | 15.5% | 14.0% | 8.0% |
| Net Income | 102.8M | 119.9M | 90.6M | 66.4M | 96.8M |
| Net Margin % | 5.5% | 7.0% | 5.7% | 4.8% | 7.9% |
| Key Metrics | |||||
| EBITDA | 311.2M | 323.1M | 267.5M | 220.8M | 221.9M |
| EPS (Basic) | $2.96 | $3.57 | $2.72 | $2.00 | $2.93 |
| EPS (Diluted) | $2.89 | $3.36 | $2.69 | $1.99 | $2.91 |
| Basic Shares Outstanding | 34735000 | 33601000 | 33320000 | 33127000 | 32993000 |
| Diluted Shares Outstanding | 34735000 | 33601000 | 33320000 | 33127000 | 32993000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Integer Holdings Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 17.2M | 46.5M | 23.7M | 24.3M | 17.9M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 346.1M | 245.3M | 238.3M | 224.3M | 182.3M |
| Inventory | 253.7M | 247.1M | 239.7M | 208.8M | 155.7M |
| Other Current Assets | 40.6M | 28.4M | 28.1M | 27.0M | 27.6M |
| Total Current Assets | 770.1M | 671.1M | 617.7M | 558.3M | 453.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 137.2M | 115.3M | 95.0M | 85.1M | 79.5M |
| Goodwill | 3.0B | 2.8B | 2.8B | 2.8B | 2.7B |
| Intangible Assets | 825.4M | 778.3M | 783.1M | 819.9M | 807.8M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 32.2M | 31.3M | 29.4M | 33.1M | 41.5M |
| Total Non-Current Assets | 2.6B | 2.4B | 2.3B | 2.2B | 2.1B |
| Total Assets | 3.4B | 3.1B | 2.9B | 2.8B | 2.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 113.1M | 101.5M | 120.3M | 110.8M | 76.9M |
| Short-term Debt | 16.9M | 21.9M | 10.6M | 29.6M | 25.7M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 13.9M | 19.0M | 8.7M | 6.2M | 5.0M |
| Total Current Liabilities | 232.0M | 227.2M | 221.0M | 223.8M | 159.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.3B | 1.1B | 1.0B | 979.1M | 880.1M |
| Deferred Tax Liabilities | 116.3M | 124.6M | 145.6M | 160.7M | 171.5M |
| Other Non-Current Liabilities | 19.9M | 25.4M | 14.4M | 13.4M | 16.3M |
| Total Non-Current Liabilities | 1.4B | 1.2B | 1.2B | 1.2B | 1.1B |
| Total Liabilities | 1.7B | 1.5B | 1.4B | 1.4B | 1.2B |
| Equity | |||||
| Common Stock | 35.0K | 34.0K | 33.0K | 33.0K | 33.0K |
| Retained Earnings | 994.1M | 891.2M | 771.4M | 680.7M | 614.3M |
| Treasury Stock | 76.9M | 0 | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.7B | 1.6B | 1.5B | 1.4B | 1.4B |
| Key Metrics | |||||
| Total Debt | 1.3B | 1.1B | 1.1B | 1.0B | 905.8M |
| Working Capital | 538.1M | 443.9M | 396.7M | 334.5M | 293.4M |
Balance Sheet Composition
Integer Holdings Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 102.8M | 119.9M | 90.6M | 66.4M | 96.8M |
| Depreciation & Amortization | 130.7M | 111.0M | 98.8M | 92.0M | 81.4M |
| Stock-Based Compensation | 23.2M | 24.8M | 23.3M | 21.0M | 16.2M |
| Working Capital Changes | -92.8M | -59.7M | -51.8M | -79.6M | -18.2M |
| Operating Cash Flow | 224.3M | 199.4M | 175.0M | 105.0M | 183.0M |
| Investing Activities | |||||
| Capital Expenditures | -91.0M | -105.3M | -119.8M | -74.1M | -53.0M |
| Acquisitions | -178.9M | -138.5M | -43.6M | -126.6M | -218.0M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | 0 | 0 | 304.0K | 0 |
| Investing Cash Flow | -269.8M | -243.9M | -163.4M | -200.4M | -271.0M |
| Financing Activities | |||||
| Share Repurchases | -50.0M | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 1.3B | 274.5M | 869.4M | 166.0M | 900.6M |
| Debt Repayment | -1.1B | -258.2M | -841.7M | -71.1M | -805.0M |
| Financing Cash Flow | 39.9M | 12.6M | -20.3M | 92.3M | 100.5M |
| Free Cash Flow | 105.1M | 99.6M | 60.3M | 41.7M | 103.2M |
| Net Change in Cash | -5.6M | -31.9M | -8.6M | -3.1M | 12.6M |
Cash Flow Trend
Integer Holdings Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
29.47
Forward P/E
11.79
Price to Book
1.67
Price to Sales
1.58
PEG Ratio
11.79
Profitability Ratios
Profit Margin
5.55%
Operating Margin
12.79%
Return on Equity
6.11%
Return on Assets
4.75%
Financial Health
Current Ratio
3.32
Debt to Equity
75.45
Beta
0.71
Per Share Data
EPS (TTM)
$2.89
Book Value per Share
$50.85
Revenue per Share
$53.37
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ITGR | 2.9B | 29.47 | 1.67 | 6.11% | 5.55% | 75.45 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Stryker | 126.3B | 39.21 | 5.62 | 15.08% | 12.92% | 72.97 |
| Masimo | 9.4B | 46.47 | 12.89 | 23.43% | -9.92% | 77.55 |
| Bio-Rad | 8.1B | 10.75 | 1.08 | 10.84% | 29.42% | 18.58 |
| Bio-Rad Laboratories | 7.6B | 10.98 | 1.11 | 10.84% | 29.42% | 18.58 |
Financial data is updated regularly. All figures are in the company's reporting currency.






